Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

NatWest and Halifax cut mortgage costs

View original at uk.finance.yahoo.com
NatWest and Halifax cut mortgage costs NatWest (NWG.L) and Halifax have both cut mortgage rates this week, while Nationwide (NBS.L) will allow buyers to borrow up to six times their income, fuelling expectations of a "booming market" in 2026…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nationwide extending six times income lending beyond first time buyers is a positive step, particularly as the first wave of Helping Hand customers starts to look at their next move

    80% confidence
  • The change to withdraw 60% LTV products was part of a reprice following the changes to swaps after the Bank of England held interest rates

    80% confidence
  • With the right advice, borrowers can use that flexibility to move sooner and secure a deal that fits both the immediate need and the longer-term plan

    80% confidence
  • The average rate for a two-year fixed mortgage came in at 4.49% this week

    80% confidence
  • The average five-year fixed deal came in at 4.99%, a drop from the previous 5%

    80% confidence
  • It supports borrowers who are constrained by income multiples rather than the monthly cost, and shows how lenders are adapting to the reality of today's housing market

    80% confidence

Data points we hold from this source

Barclays · five year mortgage rate3.79 percent
Barclays · two year mortgage rate3.57 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com